Sullivan, Sir Arthur
A Dictionary of British History
|
2004
|
|
© A Dictionary of British History 2004, originally published by Oxford University Press 2004. (Hide copyright information)
Copyright
Sullivan, Sir Arthur (1842–1900). Sullivan was born in Lambeth Walk (London), son of a professional musician at one time bandmaster at Sandhurst. Blessed with a fine voice, Sullivan was a chorister at the Chapel Royal. In 1856 he won the Mendelssohn scholarship and entered the Royal Academy of Music. In 1866 he produced his only symphony and was offered the professorship in composition at the academy. The great collaboration with
Gilbert got off to a faltering start in 1871 with
Thespis but took fire in 1875 with
Trial by Jury.
Pinafore (1878),
The Pirates of Penzance (1879), and
Mikado (1885) followed in quick succession. Sullivan's serious work continued with
The Golden Legend (1886) and
Ivanhoe (1891). The last of the collaborations,
The Grand Duke, was put on in 1896. His popular pieces included ‘Onward Christian Soldiers’ (1871) and ‘The Lost Chord’ (1877). Sullivan possessed a wealth of melody, brilliant orchestration, considerable poetry, and much humour. The serious work is good; the comic operas incomparable.
Cite this article
Pick a style below, and copy the text for your bibliography.
|
Callisto Pharmaceuticals Announces $5.14 Million Private Placement Financing of Common Stock and Warrants; Proceeds to Fund Acceleration of Clinical Trials of Drug Candidates and Expansion of Key Strategic Initiatives.
Business Wire; 2/7/2006; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...financing will be used to continue to fund Callisto's strategic initiatives, including...clinical development activities. Callisto currently has two anticancer drug candidates...
|
|
|
Callisto CEO Video Spotlights Company's Drug Candidates to Treat Devastating Multiple Myeloma and Leukemia Blood Cancers; Drugs under Development as New Therapies for Patients Who Fail to Respond to Existing Treatments.
Business Wire; 10/14/2005; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...video, CEO Dr. Gary S. Jacob outlines Callisto's drug development programs and describes...developed to fill this treatment void. "Callisto has assembled a world-class team of...
|
|
|
Callisto Announces First Berlin Issues Research Update Following Company's Announcement of New Data on Cancer Drug Efficacy; Independent German Based Equity Research Firm Maintains Buy Rating and Share Price Target of $2.50.
Business Wire; 3/2/2006; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...issued the research update following Callisto's announcement that researchers in...the liver and gastrointestinal tract. Callisto is also developing Atiprimod as a therapy...
|
|
|
Callisto Announces Availability of Presentation Outlining Drug Development Pipeline and Market Opportunities; Development Programs Include New Drugs to Treat Leukemia and Multiple Myeloma Cancers, and to Fight Biowarfare Threats.
Business Wire; 10/13/2005; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...drug to treat forms of leukemia. "Callisto is developing drugs such as Atiprimod...said Dr. Gary S. Jacob, CEO of Callisto. "There are significant numbers of...
|
|
|
Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of $3.00 and Buy Rating; Analyst Cites Recent Callisto Announcement of Encouraging Anti-Tumor Response of Drug Candidate Atiprimod.
Business Wire; 3/13/2006; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...ago. The new target in part reflects Callisto's recent announcement of clinical...Research issued the update following Callisto's announcement that researchers in...
|
|
|
Callisto Names Veteran Investment Banker and Biotech Specialist Dan D'Agostino to Key Technology and Business Growth Role; D'Agostino to Direct M&A and Efforts to Expand Callisto Pipeline of New Drug Technologies and Candidates.
Business Wire; 10/14/2005; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...portfolio. Mr. D'Agostino brings Callisto approximately 15 years' experience...sector will be an invaluable asset to Callisto as we continue to execute our business...
|
|
|
Callisto Announces Appointment of Dr. Arthur Sytkowski as Clinical Trial Advisor and Medical Safety Monitor; Veteran Scientist and Harvard Professor to Guide Callisto's Expanding Clinical Programs for Atiprimod and L-Annamycin.
Business Wire; 3/9/2006; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...University, has agreed to serve as Callisto's Clinical Trial Advisor and Medical...Monitor. Dr. Sytkowski will advise on Callisto's expanding clinical programs to develop...
|
|
Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of US$3.00 and Buy Rating.
PR Newswire Europe; 3/14/2006; 700+ words
; ...PRNewswire/ -- - Analyst Cites Recent Callisto Announcement of Encouraging Anti...Response of Drug Candidate Atiprimod Callisto Pharmaceuticals, Inc. (Amex...The new target in part reflects Callisto's recent announcement of clinical...
|
|
|
Callisto Issues Updated Investor Fact Sheet to Reflect Recent Clinical Progress of Cancer Drug Candidate Atiprimod; Drug's Clear Response Against Carcinoid Tumors and Newly Planned Clinical Development Direction Noted in Fact Sheet.
Business Wire; 3/2/2006; 700+ words
; NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL...drug candidates. E[acute accent]Callisto recently announced plans to launch an...carcinoid patients. E[acute accent]The Callisto Investor Fact Sheet provides a succinct...
|
|
Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of $3.00 and Buy Rating.
PR Newswire; 3/14/2006; 700+ words
; Analyst Cites Recent Callisto Announcement of Encouraging Anti...March 14 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL...ago. The new target in part reflects Callisto's recent announcement of clinical...
|
|
Callisto
Book article from: A Dictionary of Astronomy
Callisto The second-largest satellite of Jupiter...same face turned towards the planet. Callisto is 4819 km in diameter but...because of its low albedo of 0.2. Callisto's density is 1.83 g...
|
|
Galilean satellites
Book article from: A Dictionary of Earth Sciences
...classical satellites Io, Europa, Ganymede, and Callisto (in order outwards from Jupiter) which were...decrease in density from Io (3550 kg/m 3 ) to Callisto (1830 kg/m 3 ), Callisto preserving one of the most heavily cratered surfaces...
|
|
Astrobiology
Encyclopedia entry from: The Gale Encyclopedia of Science
...Antarctic have been identified on Jupiter ’ s moons Callisto, Europa, and Ganymede. Thanks to the Galileo space probe...1995 to 2003, we now there are subsurface oceans of liquid on Callisto and Europa. These oceans are considered prime locations for...
|
|
|
Voyager Spacecraft
Encyclopedia entry from: The Gale Encyclopedia of Science
...relatively thin layer of ice over a watery world-ocean. Ganymede and Callisto, consisting mostly of ice, were found to contain fascinating geology of their own. Callisto, thanks to data obtained in 1998 by the space probe Galileo, is now...
|
|
Space and Planetary Geology
Book article from: World of Earth Science
...geological time scales for Mercury, Venus, the Moon, and Mars. Similar studies are underway for the large Jovian satellites (Callisto, Ganymede, and Europa), the Saturnian satellites (Mimas, Enceladus, Tethys, Dione, Rhea, and Iapetus), the Uranian...
|
